Amylases

• 

  Subject Areas on Research

  • Beneficial effects of cholecystokinin-receptor blockade and inhibition of proteolytic enzyme activity in experimental acute hemorrhagic pancreatitis in mice. Evidence for cholecystokinin as a major factor in the development of acute pancreatitis. 
  • Beta adrenergic stimulation of protein carboxymethylation and amylase secretion in rat parotid gland. 
  • Bioassay of plasma cholecystokinin in rats: effects of food, trypsin inhibitor, and alcohol. 
  • Capsaicin vanilloid receptor-1 mediates substance P release in experimental pancreatitis. 
  • Characterization of canine intestinal cholecystokinin-58 lacking its carboxyl-terminal nonapeptide. Evidence for similar post-translational processing in brain and gut. 
  • Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction. 
  • Clinical experience with human anodal trypsinogen (HAT) for detection of pancreatic allograft rejection. 
  • Correlation of serologic and urinary tests with allograft biopsy in the diagnosis of pancreas rejection. 
  • Efficacy of human anodal trypsinogen for detection of rejection in clinical pancreas transplantation. 
  • Evidence that CCK-58 has structure that influences its biological activity. 
  • Extensive investigation of patients with mild elevations of serum amylase and/or lipase is 'low yield'. 
  • Identification of nonsulfated cholecystokinin-58 in canine intestinal extracts and its biological properties. 
  • Integrated actions of cholecystokinin on the gastrointestinal tract: use of the cholecystokinin bioassay. 
  • Natural and synthetic CCK-58. Novel reagents for studying cholecystokinin physiology. 
  • Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. 
  • Origin of pleural fluid amylase in esophageal rupture. 
  • Pancreatic digestive enzyme gene expression: effects of CCK and soybean trypsin inhibitor. 
  • Pancreatic growth: interaction of exogenous cholecystokinin, a protease inhibitor, and a cholecystokinin receptor antagonist in mice. 
  • Pancreatic secretory trypsin inhibitor I reduces the severity of chronic pancreatitis in mice overexpressing interleukin-1β in the pancreas. 
  • Parathyroid hormone secretion and target organ response in experimental acute pancreatitis. 
  • Primary sensory neurons: a common final pathway for inflammation in experimental pancreatitis in rats. 
  • Relative bioactivities of cholecystokinins-8 and -33 on rat pancreatic acini. 
  • Results of solitary pancreas transplantation with enteric drainage: is there a benefit from monitoring urinary amylase levels? 
  • Sequence variation outside the "active" region of dog and rabbit cholecystokinin-58 results in bioactivity differences. 
  • Simultaneous pancreas-kidney (SPK) transplantation from controlled non-heart-beating donors (NHBDs). 
  • Synthesis of human CCK26-33 and CCK-33 related analogues on 2,4-DMBHA and TMBHA. 
  • The pleuropulmonary consequences of esophageal rupture: an experimental model. 
  • Total synthesis, purification, and characterization of human [Phe(p-CH2SO 3Na)52, Nle32,53,56, Nal55]-CCK20-58, [Tyr52, Nle32,53,56, Nal55]-CCK-58, and [Phe(p-CH2SO3Na)52, Nle32,53,56, Nal55]-CCK-58. 
  • Transgenic expression of pancreatic secretory trypsin inhibitor-1 rescues SPINK3-deficient mice and restores a normal pancreatic phenotype.